Compare · ICUI vs RMD
ICUI vs RMD
Side-by-side comparison of ICU Medical Inc. (ICUI) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICUI and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 8.1x ICUI ($4.18B).
- Over the past year, ICUI is up 37.8% and RMD is down 10.8% - ICUI leads by 48.6 points.
- RMD has hit the wire 9 times in the past 4 weeks while ICUI has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 15 for ICUI).
- Company
- ICU Medical Inc.
- ResMed Inc.
- Price
- -
- -
- Market cap
- $4.18B
- $34.07B
- 1M return
- +6.66%
- +4.60%
- 1Y return
- +37.78%
- -10.84%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 1992
- News (4w)
- 0
- 9
- Recent ratings
- 15
- 25
ICU Medical Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, including sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation, such as sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. In addition, the company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical Mednet, an enterprise medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. Further, it provides critical care products comprising Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest ICUI
- VP, General Counsel Sanzone Virginia Ruth sold $819,150 worth of shares (4,856 units at $168.69) as part of a pre-agreed trading plan, decreasing direct ownership by 25% to 14,604 units (SEC Form 4)
- Chief Financial Officer Bonnell Brian Michael sold $1,116,675 worth of shares (6,381 units at $175.00) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 56,062 units (SEC Form 4)
- Chief Financial Officer Bonnell Brian Michael sold $1,608,143 worth of shares (9,307 units at $172.79) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 62,443 units (SEC Form 4)
- ICU Medical to Participate in Upcoming Investor Conferences
- VP, GM-Infusion Capital Woolson Daniel sold $982,265 worth of shares (5,417 units at $181.33), decreasing direct ownership by 24% to 17,062 units (SEC Form 4)
- Chief Information Officer Sousa Ben sold $401,209 worth of shares (2,250 units at $178.32), decreasing direct ownership by 42% to 3,076 units (SEC Form 4)
- Chief Operating Officer Voigtlander Christian B. sold $1,633,404 worth of shares (8,929 units at $182.93), decreasing direct ownership by 19% to 37,377 units (SEC Form 4)
- Director Finney Elisha W sold $68,978 worth of shares (378 units at $182.48), decreasing direct ownership by 7% to 4,871 units (SEC Form 4)
- SEC Form 10-Q filed by ICU Medical Inc.
- ICU Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target